inTervieW - Green Cross Publishing

More documents

Recommendations

Info

36 pRoducT news ‘Change one thing’ information pack launched for patients with high blood pressure Sanofi-aventis has launched a new patient advice tool for doctors and nurses treating patients with high blood pressure under the Triapin brand. The Change One Thing pack provides physicians with ready-made patient advice literature for those patients who may need to adapt their lifestyle to help lower their blood pressure. Change One Thing provides advice across five lifestyle areas in the management of blood pressure – salt intake; smoking; stress reduction, being more active, and; complying with medications. Patients are often presented with a range of lifestyles habits to adapt in one go. It can be hard to maintain these changes. Change One Thing pack helps to achieve this. The doctor or nurse enters an agreement with the patient on changing one lifestyle habit over an agreed period of time by giving only one item from the pack. When this becomes a new habit a new item can be added and so on. Dr Garrett Hayes lent his support to the launch of the news tool and he said: “The EUROASPIRE study has demonstrated a high prevalence of modifiable risk factors in coronary heart disease patients. We have seen the positive impact made on the treatment of coronary heart disease through statins and other medications, but there has not been a corresponding improvement in patient lifestyle management.” Dr Velichka Valcheva, Medical Director of sanofi-aventis said: “Our goal is to assist doctors in delivering meaningful, lasting lifestyle advice to their patients” If you would like a Change One Thing pack sent to you, please contact Celine Reilly at 01 403 5600 or email celine.reilly@sanofi-aventis.com. Caption Dr Garrett Hayes, with Elaine Ryan, sanofi-aventis and Dr Elen Shiryayeva also of sanofi-aventis. Centrum – supplies restored Pfizer Consumer Healthcare has announced that supplies of Centrum are being restored. Initially, Centrum Advance and Centrum Select 50+ will be available from the beginning of november from your usual wholesaler. Supplies of Centrum Junior and Centrum Cardio will follow shortly thereafter. Following resumption of shipping, batch numbering will be as follows: • for Centrum Advance, the last three digits will read 103 and above. • for Centrum Select 50+, the last three digits will read 090 and above. Only product with lot numbers corresponding to the above numbering system should be sold to consumers. The full Centrum range will now comprise the following four products (pictured); Centrum Advance (30s and 60s packs); Centrum Select 50+ (30s and 60s packs); Centrum Junior (30s pack) and Centrum Cardio (60s pack). Full product details are available from Pfizer Consumer Healthcare representatives and from the IPU data base. Customers can be assured that Pfizer is committed to driving Centrum sales growth and will be supporting the brand with a high level of marketing support over the coming months. issue 10 volume 12 • novemBeR 2010 Roger & Gallet – Christmas Coffret Roger & Gallet Christmas Coffrets are available in three different Roger & Gallet fragrances – their signature scent, Jean Marie Farina which is refreshing, their fragrance for invigoration – Bois D’Orange and Rose with relaxing properties. Each Coffret contains 30ml Eau de Cologne, 100ml perfumed soap and 75ml perfumed luxurious bath & shower gel. Rose Christmas Coffret Jean Marie Farina Christmas Coffret Bois D’Orange Christmas Coffret Roger & Gallet, whose perfumes promote well-being through the powers of Aromachology, recently launched in pharmacies in Ireland. Concentrated in rare natural essences and essential oils, these fragrant ranges offer a complete sensory experience: perfumed waters, as well as round and liquid soaps, shower gels and body milks. Each Coffret contains 30ml Eau de Cologne, 100ml perfumed soap, and a 75ml perfumed luxurious shower & bath gel. – Eau de Cologne 30ml – Roger & Gallet’s fragranced waters with recognized properties of Aromachology channel the art of well-being through fragrance. – Perfumed soaps – delicately wrapped in pleated silk paper and manufactured using the traditional “cauldron method” and fragranced using a process that seals natural essential oils into the heart of the soap, so as to keep the fragrance intact and maintain its authenticity throughout its use. The soap’s highly extended life-span results from a manufacturing technique kept secret by the brand for over a century. The 100 per cent vegetal-based formula enriched with essential oils does not dry out the epidermis, it leaves skin feeling sublimely soft. – Perfumed bath and shower gels – Roger & Gallet bath and shower gels gently cleanse the skin. For optimum comfort, a calcium ion complexing agent is incorporated into the formula to help prevent skin from drying out. Their texture lends itself to being massaged over skin under the shower, procuring an invigorating sensation of well-being. www.medical
issue 10 volume 12 • novemBeR 2010 Prolia: unique new treatment for post-menopausal osteoporosis now reimbursed in Ireland Amgen Ireland and GlaxoSmithKline (Ireland) ltd (GSK) recently announced that denosumab has become available in Ireland to treat osteoporosis in postmenopausal women at increased risk of fracture and will be reimbursed under the General Medical Services and Drugs Payment Schemes. In Ireland, more than 300,000 people have osteoporosis. Despite the availability of treatment options, many of these women experience fractures due to poor compliance with therapy. With proven efficacy and a six-monthly injection, denosumab offers women with osteoporosis a new alternative to current treatments. Denosumab works in a different way from other osteoporosis treatments. It is the first and only approved therapy that specifically targets RAnK ligand, an essential regulator of osteoclasts (the cells that break down bone). Denosumab helps stop the process that causes bone loss throughout the skeleton, resulting in greater bone density, stronger bones, and reduced risk for fractures at the spine, hip and other non-vertebral sites. The reimbursement for denosumab follows a review of the therapy’s cost-effectiveness by the national Centre for Pharmacoeconomics (nCPE) for the prevention of osteoporotic fractures in postmenopausal women and will be available on both the GMS and DPS schemes as of October 1st. Discussing denosumab, specialist in bone health at St James’s Hospital, Professor Bernard Walsh said: “It is good to have another proven therapeutic arm available to us in the treatment of osteoporosis. The clinical study results are impressive and confirm the efficacy of the use of a monoclonal antibody treatment in this disease.” Dr Gillian Darling, GP Specialist in Women’s Health in leopardstown and the Dublin Well Woman Centres commented: “As most osteoporosis patients are treated in primary care it is an advantage to have a treatment that can be administered in the GP surgery as well as the hospital clinic setting. “Recent studies would seem to point to a strong efficacy and good tolerability profile of denosumab in the treatment of osteoporosis in post-menopausal women.” Denosumab, which is being co-marketed in Ireland by Amgen and GSK, marks an innovative approach to the treatment of post menopausal osteoporosis. Statistics show that 90 per cent of hip fractures in senior citizens are due to osteoporosis and that one in five patients suffering hip fracture die within four months and 30 per cent within a year. For more information on denosumab’s reimbursement, please visit www.ncpe.ie ClonMedica now distributing Hedrin and Virasoothe Thornton & Ross ltd (T&R) are pleased to announce the appointment of ClonMedica, the OTC Division of Clonmel Healthcare Company ltd as its distributor in the Republic of Ireland for the Hedrin range of head lice treatments and Care Virasoothe Chicken Pox Relief Cooling Gel. The change is effective from 1st november after which all orders should be sent to Clonmel Healthcare. T&R would like to thank Allphar Services ltd for establishing these products in Ireland. Allphar will remain as T&R’s distributor for the rest of its pharmacy range including the market leading Galfer and Cerumol brands. Commenting on the change Rob Purkis, European Market Development Manager for T&R, says that the move reflects the synergy of Hedrin and Virasoothe with ClonMedica’s successful children’s product range and the Company’s contacts with a range of healthcare professionals. A similar approach in the UK has made Hedrin the market leading head lice treatment1 and is establishing the more recently launched Virasoothe which is clinically proven to relieve the symptoms of chicken pox. T&R is keen to communicate the clinically proven benefits of these products to a wider group of healthcare professionals than has been possible before and this has been a key factor in the appointment of ClonMedica. Martin Gallagher, Marketing and Sales Director of Clonmel Healthcare ltd, commenting on the appointment, expressed his enthusiasm for this new venture and is confident that this addition to the Company’s range of children’s product will result in greater understanding of the benefits of Hedrin and Virasoothe amongst healthcare professionals. pRoducT news Multaq – first-line option in new 2010 ESC Guidelines for the Management of Atrial Fibrillation Sanofi aventis announced recently that the European Society of Cardiology (ESC) 2010 new Guidelines for the Management of Atrial Fibrillation (AF) have been released and recommend that Multaq (dronedarone) should be used for maintenance of sinus rhythm as a first-line treatment option in all patients with paroxysmal and persistent AF (class of recommendation I, level of evidence A) other than those with CHF nyHA class III/IV or unstable CHF nyHA class II (class of recommendation III, level of evidence B). Multaq was granted a Class I recommendation, a designation assigned in the guidelines when “there is evidence and/or general agreement that a given procedure/therapy is beneficial, useful, and effective.” The Task Force for the Management of Atrial Fibrillation of the ESC recognised the extensive clinical development of Multaq, giving it their highest ranking A for level of evidence. Moreover, the guidelines recommend that Multaq may also be used to achieve rate control in non-permanent AF except for patients with nyHA class III – IV or unstable heart failure (class of recommendation IIa, level of evidence B). Importantly the new guidelines include, for the first time, a statement on the importance of reducing hospitalisation as a key therapeutic goal in the management of AF. They also state that Multaq should be considered in order to reduce cardiovascular hospitalisation in patients with nonpermanent AF and cardiovascular risk factors (Class of recommendation IIa, level of evidence B) as well as in patients with AF and stable heart failure (nyHA Class I, II) (Class of recommendation IIa, level of evidence C). 1 The guidelines do not recommend use of Multaq in patients with nyHA class III and IV or with recently unstable (decompensation within the prior month) nyHA class II heart failure. “Sanofi-aventis is pleased with this first-line recommendation for Multaq in the AF guidelines which recognises the extensive clinical development for the product as well as the innovative outcome of reducing cardiovascular hospitalisation as demonstrated in the ATHEnA trial,” said Marc Cluzel, Executive Vice President, Research and Development, sanofi-aventis. Xamiol 60g Gel discontinued lEO Pharma has announced that Xamiol Gel 60g will be discontinued from november 2010. Please note that Dovobet Gel 60g will continue to be available. Dovobet Gel 60g contains the identical product form, active ingredients and strength as Xamiol (calcipotriol/bethamethasone dipropionate). Dovobet Gel is indicated for both scalp and mild to moderate body plaque psoriasis. The price is also identical. This discontinuation is not due to any safety or quality issues with Xamiol Gel, therefore pharmacists and patients may continue to dispense or use Xamiol Gel that they currently have. If you require any further information, please contact the Marketing Department at 01 4908924 or email paul.kirwan@lEO-Pharma.com independent.ie 37
Page 1 and 2: issue 10 volume 12 novemBeR • 201
Page 3 and 4: The independenT monThly foR iRish p
Page 5 and 6: NEW Won’t irritate your stomach l
Page 7 and 8: INTRODUCE YOUR CUSTOMERS TO A BRIGH
Page 9 and 10: Cymex Cream has a Triple Action For
Page 11 and 12: QicPOS.net Customer Loyalty Card Lo
Page 13 and 14: RoC ® SUBLIME ENERGY EYE EYELIDS
Page 16 and 17: 16 heRBal medicine Adding spice to
Page 18 and 19: 18 inTeRview In part two of our ser
Page 20 and 21: 20 opinion tHe CoAlfACe brain drain
Page 22 and 23: 22 PINIoN opinion vIew froM Above P
Page 24 and 25: 24 law lAw Treating children - the
Page 26: 26 finance How safe are your invest
Page 29 and 30: When it comes to Pharmacies, we do
Page 31 and 32: issue 10 volume 12 • novemBeR 201
Page 33 and 34: Date of preparation: April 2010 Tev
Page 38 and 39: 38 classifieds/cRosswoRd DaTes For
Page 40: 40 opinion O’Sean’S eleven We

inTervieW - Green Cross Publishing

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?